Figure 3.
Specific recognition of MICA/B on C1R transfectants by the Vδ1 γδ T cell lines BTδ1, LTδ1, and OTδ1 derived from carcinomas of breast, lung, and ovary, respectively (A–D). The data from chromium release assays shown were representative of numerous experiments with these T cell lines and others derived from prostate and colon carcinomas, which all were tested against the C1R-MICA and C1R-MICB targets. Cytotoxicity was inhibited in the presence of mAb 2C10 (anti-MICA) or mAb 6D4 (anti-MICA and -MICB) but not with control Ig. (E) No responses were seen with the tumor-derived CD8+ αβ T cell lines; as one example, data obtained with the breast tumor-derived BTαβ line are shown. (F) The ovary tumor-derived Vδ2 γδ T cell line (OTδ2) showed no increased response against C1R-MICA targets. E:T, effector-to-target cell ratio. See text for further explanation.